Skip to content
WorldBrand.AI

Catalyst Pharmaceuticals

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2019

    Public controversy over Firdapse pricing

    Firdapse pricing became a public controversy after Senator Bernie Sanders asked Catalyst to explain the cost of the medicine, which had previously been available to some patients through compassionate-use access. Catalyst responded that FDA approval provided broader formal access to the treatment. The issue reflected wider debate about orphan-drug pricing, exclusivity, and affordability.

    Source